19:50 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

VBI's CMV vaccine induces 100% seroconversion in Phase I

VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV) reported interim data from a single-blind, Canadian Phase I trial in 128 cytomegalovirus (CMV)-negative healthy volunteers showing that 2 μg intramuscular VBI-1501A (CMV eVLP) with aluminum phosphate adjuvant led to...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

CMV eVLP: Completed Phase I enrollment

VBI completed enrollment of 128 CMV-seronegative healthy volunteers in a placebo-controlled, Canadian Phase I trial evaluating unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A given at months 0, 2 and 6. VBI Vaccines Inc. (NASDAQ:VBIV;...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

CMV eVLP: Phase I ongoing

A DSMB recommended continuation of a placebo-controlled, Canadian Phase I trial evaluating unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A given at months 0, 2 and 6. The trial is enrolling about 125 CMV-seronegative healthy...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

CMV eVLP: Phase I started

VBI began a placebo-controlled, Canadian Phase I trial to evaluate unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A given at months 0, 2 and 6 in about 125 CMV-seronegative healthy adult volunteers. VBI Vaccines Inc....
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

VBI Vaccines, SciVac deal

SciVac will acquire vaccine company VBI in a stock deal. The combined company will change its name to VBI Vaccines Inc. and focus on developing vaccines for infectious diseases and cancer. Each VBI share will...